Your Cart is Empty

Back To Shop

Trenon A 100mg/ml 10 ml (Trenbolone Acetate) – Medical Pharma Steroid in USA


C20H24O3 = 312.4.
CAS — 10161-33-8 (Trenbolone); 10161-34-9 (Trenbolone Acetate).


USP 31 (Trenbolone Acetate). Solution oily transparent color from light yellow to yellow, with characteristic odor. It should be stored at temperatures of 2° to 8°C for optimal storage conditions.

Trenon A contains: 100mg 100 mg / ml Trenbolone acetate.

Trenon A 100mg/ml 10 ml (Trenbolone Acetate) – Medical Pharma Steroid in USA


Trenon A pharmacologic category


Dosing and administration:

Deep intramuscular injection.  50-200mg once a week every 2 to 4 weeks.

Dosing: Renal impairment

No dosage adjustment provided in manufacturer’s labeling; use with caution due to propensity to cause edema.

Dosing: Hepatic impairment

No dosage adjustment provided in manufacturer’s labeling; use with caution.


Trenbolone acetate has been used as an anabolic agent in practice.

It is administered through deep intramuscular injection and is used to improve body weight, feed conversion and nitrogen retention 60-90 days. It is used alone or in combination with another hormonally active ingredient.


Store in airtight containers at room temperature.


Hypersensitivity to trenbolone, benzyl alcohol or any component of the formulation.

Men with carcinomas of the breast or with known or suspected carcinomas of the prostate; women who are or may become pregnant.

Documentation of allergenic cross-reactivity for androgens is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.


Hepatic effects: Prolonged use and/or high doses may cause peliosis hepatis or liver cell tumors, which may not be apparent until liver failure or intra-abdominal hemorrhage develops. Discontinue in case of cholestatic hepatitis with jaundice or abnormal liver function tests.

Venous thromboembolism: Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported with testosterone products. Evaluate patients with symptoms of pain, edema, warmth, and erythema in the lower extremity for DVT and those with acute shortness of breath for PE. Discontinue therapy if a venous thromboembolism is suspected.

Disease related concerns:

Breast cancer: Use with caution in patients with breast cancer; may cause hypercalcemia by stimulating osteolysis.

Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention.

Hepatic impairment: Use with caution in patients with hepatic impairment.

Pregnancy risk factor


Category X: Studies in animals or human beings have demonstrated fetal abnormalities, or there is evidence of fetal risk based on human experience, or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

Pregnancy considerations

Use is contraindicated in women who are or may become pregnant; masculinization of the fetus has been reported.


Excretion in breast milk unknown/not recommended.

Adverse reactions

Frequency unknown.

Cardiovascular: Edema.

Central nervous system: Depression, excitation, insomnia.

Dermatologic: Acne (females and prepubertal males).

Also reported in females: Hirsutism, male-pattern baldness.

Endocrine & metabolic: Electrolyte imbalances, glucose intolerance, gonadotropin secretion inhibited, gynecomastia, HDL decreased, LDL increased, libido changes.

Also reported in females: Clitoral enlargement, menstrual irregularities.


Prepubertal males: Increased or persistent erections, penile enlargement.

Postpubertal males: Bladder irritation, epididymitis, impotence, oligospermia, priapism (chronic), testicular atrophy, testicular function inhibited.

Hematologic: Prothrombin time increased, suppression of clotting factors.

Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, bilirubin increased, cholestatic jaundice, hepatic necrosis (rare), hepatocellular neoplasms, peliosis hepatis (with long-term therapy).

Neuromuscular & skeletal: CPK increased, premature closure of epiphyses (in children).

Renal: Creatinine excretion increased.

Metabolism/Transport effects

None known.

Drug interactions

Corticosteroids, Warfarin and Antidiabetic agents.

Test interactions

May suppress factors II, V, VII, and X; may increase PT; may decrease thyroxine-binding globulin and radioactive iodine uptake.

Monitoring parameters

Liver function tests, cholesterol profile, hemoglobin/hematocrit; INR/PT in patients on anticoagulant therapy.

Children: Radiographs of left wrist and hand every 6 months (to assess bone maturation).

Adult females: Signs of virilization (deepening voice, hirsutism, acne, clitoromegaly); urine and serum calcium in women with breast cancer.

Dosage forms

Injectable solution – 100mg/1ml and 30mg/1ml (contains benzyl alcohol).

Anatomic Therapeutic Chemical (ATC) Classification


Mechanism of action

Anabolic steroid derived from Nandrolone, sharing some properties. Characterized by its androgenic and anti-glucocorticoid activity with the ability to promote growth up to 20% in animal studies.


Trenbolone acetate upon entering the circulatory system is rapidly hydrolysed to its free active form, trenbolone (TB0H). In the rat the 173-epimer is the major metabolite.

Metabolism: Hepatic.

Elimination: Bile (80%).

Half-life: 2 weeks.

Buy steroids online USA.


Your Cart is Empty

Back To Shop